University Of Maryland, Baltimore

University Of Maryland, Baltimore — doing business as Baltimore Campus is a state-controlled institution of higher learning that operates as the prime recipient on federal research grants and contracts, with a 2.65 billion dollar combined potential value across 4,190 total awards spanning basic biomedical research, clinical trials, professional education, and specialized laboratory services delivered to 161 distinct federal customer agencies through the Baltimore campus location in Maryland.

As a child entity of the University System of Maryland, UMB competes predominantly in full-and-open federal R&D procurement, with no set-aside posture evident across the award portfolio. The institution functions as a prime on 83% of recent awards and as a subcontractor on 17%, establishing it as a substantial independent federal performer rather than a feeder contractor. Award activity has accelerated markedly—from 224 awards in 2022 to 337 in 2024, though 2025–2026 shows 104 awards year-to-date, reflecting the typical seasonal lag in award announcements. The recompete cliff presents material risk: 311 awards worth $294.9 million combined potential value complete within the next twenty-four months.

Customer concentration clusters around National Institutes of Health agencies. The National Institute of Allergy and Infectious Diseases (NIAID) leads by dollar value at $1.44 billion combined potential across 383 awards, followed by the Veterans Health Administration's Veterans Integrated Service Network 5 at $89.7 million and the National Institute on Drug Abuse at $82 million. The top five funding agencies account for approximately 64% of combined potential value. This heavy concentration in health research reflects UMB's positioning as an academic medical center; NIH funding dominates the portfolio, with NIAID alone representing 54% of the top-customer-by-value total.

Capability portfolio centers on federally funded biomedical research, clinical trial management, vaccine development, medical education, and specialized laboratory and diagnostic services. Representative work includes a $30.3 million cost-no-fee definitive contract from the National Institute on Drug Abuse (awarded November 2025, performing through October 2030) to establish and operate the NIH NeuroBank Brain and Tissue Repository, acquiring and distributing central nervous system tissue samples for neurological research across diverse populations; a $4.52 million Defense Health Agency project grant (awarded September 2025, performing through September 2029) for a Phase 1 clinical trial of trispecific CAR T cells targeting relapsed/refractory B cell lymphoma; and a $1.27 million Food and Drug Administration definitive contract (awarded September 2025, performing through September 2028) for noninvasive fingerprinting of aluminum-adjuvanted vaccines using analytical chemistry methods. SCI-reportable invoiced revenue across service contracts captured above the $150,000 threshold totaled $62.8 million over FY2022–FY2024 (21.3M, 20.8M, and 20.7M respectively), with median government-paid hourly rates around $87.81/hr and a spectrum spanning $19.73/hr (10th percentile) through $229.44/hr (90th percentile), indicating a mix of research labor, clinical personnel, and specialized professional services. The SCI dataset shows approximately 84–358 FTEs delivered to the federal government across FY2022–FY2024, with notable expansion in FY2024.

Named vehicle positions include two active Blanket Purchase Agreements: a $12 million single-award BPA with Veterans Integrated Service Network 5 (awarded November 2023, performing through October 2028) for reagents, supplies, laboratory services, instrumentation, and veterinary care supporting VA Baltimore research; and a $245,000 single-award BPA with the Uniformed Services University of the Health Sciences (awarded July 2023, performing through June 2028) providing cadaver support services for military medical training. The Vaccine and Treatment Evaluation Units vehicle carries 30 task orders worth $78.6 million combined potential value, and the Navy's Indefinite Delivery Contract N0014001GL643 holds 196 task orders valued at $16.9 million, establishing UMB as a recurring performer on both health research and defense medical platforms.

Teaming pattern: UMB operates as a prime across most work but engages subcontractors on approximately 4% of federal service contract hours, indicating the institution largely builds its own delivery infrastructure rather than relying on subs. Named sub-award primes in the recent footprint include The Johns Hopkins University (multiple collaborative grant sub-awards on malaria vaccine epitopes, autism cerebellar research, dementia biomarkers, and other neuroscience initiatives); University of Pittsburgh (surgical rehabilitation research, infectious disease consortia leadership, cancer genomics); Peraton Inc. (space communications network systems engineering); and The Children's Hospital Corporation (vaccine adjuvant research). UMB operates as a sub-recipient on NIH and other grant programs where it provides analytical, clinical trial, or research services under prime recipients' direction—a pattern consistent with academic health system portfolio depth.

Federal grant footprint is substantial and diverse. Recent grants span the National Institute of Allergy and Infectious Diseases (NIAID grants on Mycoplasma genitalium pathology, coronavirus pan-neutralizing nanobodies, malaria vaccine epitope prediction, filarial parasite biology, and HPV immunity in transgender populations); the National Institute on Drug Abuse (cocaine relapse mechanisms, opioid-gabapentin polypharmacy, prenatal cannabis and maternal bonding, substance use social interactions); the National Institute on Aging (Alzheimer's disease olfactory dysfunction predictors, hyperpolarization-activated channel aging, caregiving interventions, vascular contributions to cognitive impairment); the National Cancer Institute (pancreatic precancer omics, CAR T cell trogocytosis, circadian rhythms in cancer fatigue); and the National Institute of Neurological Disorders and Stroke (brain organoid transplantation for chronic stroke, STRADA protein in neuron migration, cGAS signaling in TBI neuroinflammation). The Defense Health Agency, National Heart, Lung, and Blood Institute, National Institute of General Medical Sciences, National Institute on Alcohol Abuse and Alcoholism, and Fogarty International Center round out the grantor base. Grant work engages both domestic basic and translational research and international capacity-building initiatives (Fogarty awards on surgical science training in West Africa and research ethics in Morocco).

Activity trajectory reflects institutional maturity and re-competition exposure. The growth from 224 awards (2022) to 337 (2024) shows strong federal customer appetite for UMB's research and clinical services; the 104 awards recorded for 2025–2026 (year-to-date) represents a seasonal snapshot rather than decline. The $294.9 million recompete cliff in the next twenty-four months signals material revenue at risk, requiring sustained business development across NIAID, NIH, VA, Navy, and other customer bases to maintain the portfolio's dollar velocity.

UMB's institutional role as a state university-affiliated academic medical center with schools of medicine, nursing, pharmacy, dentistry, law, and social work underpins its capability breadth. The vendor operates primarily through internal delivery of research, clinical, educational, and laboratory services, rarely subcontracting core work, and maintains long-standing relationships with NIH, DoD, and VA through established vehicles and direct awards. No ownership or SBA designations apply—UMB is a public institution within the University System of Maryland governance structure.